The relationship between P-glycoprotein expression and malignancy is controversial. We have recently found that, in osteosarcoma, multidrug resistance (MDR) is associated with a less aggressive behavior, both in vitro and in clinical settings. In this study, we evaluated whether P-glycoprotein overexpression has a cause-eect relationship with the reduced metastatic potential of MDR cells, or rather re¯ects a more complex phenotype. MDR1 gene-transfected osteosarcoma cell clones, showing dierent levels of P-glycoprotein expression, were analysed for their in vitro characteristics and their tumorigenic and metastatic ability in athymic mice. Apart from the dierent levels of P-glycoprotein, no signi®cant change in the expression of surface antigens or in the dierentiative features were observed in the MDR1 gene transfectants compared to the parental cell lines or control clones, obtained by transfection with neo gene alone. In contrast to controls, however, MDR1 transfectants showed a signi®cantly lower ability to grow in semi-solid medium and were completely unable to grow and give lung metastases in athymic mice. These ®ndings indicate that P-glycoprotein overexpression is causally associated with a low malignant potential of osteosarcoma cells, and open new insights on the role and functions of P-glycoprotein activity.
Introduction P-glycoprotein, a 170 kDa plasma membrane component encoded by the MDR1 gene (Chen et al., 1986) , is a member of the ATP-binding cassette (ABC) superfamily of transporters, a large group of proteins that mediate the selective movement of solutes across biological membranes (Higgins, 1992) . Many ABC proteins are of considerable clinical relevance: mutations of the cystic ®brosis transmembrane regulator (CFTR) gene are involved in the pathophysiology of cystic ®brosis (Riordan et al., 1989) , a mutant sulphonylurea receptor SUR is implicated in persistent hyperinsulinemic hypoglycemia of infancy (Thomas et al., 1995) , the Pgh1 protein of Plasmodium falciparum contributes to resistance to chloroquine (Foote et al., 1989) , the human P-glycoprotein confers resistance of cancers to chemotherapeutic drugs. The ABC transporters play important roles in dierent biological processes, such as the uptake of nutrients, the extrusion of noxious compounds, the secretion of toxins, the transport of ions and peptides. Although the physiological function of P-glycoprotein is still largely unknown, the peculiar expression of this protein in some organs suggests a tissue-speci®c involvement in cellular transport mechanism (Gottesman and Pastan, 1993) . Better known is the role of P-glycoprotein in the phenomenon of multidrug resistance (MDR) of tumor cells to anticancer agents. Gene transfer experiments have clearly shown that the expression of the MDR1 gene product is sucient for the establishment of the MDR phenotype (Ueda et al., 1987; Pastan et al., 1988) , in which resistance to a broad spectrum of hydrophobic compounds is due to a reduced intracellular drug accumulation that is mediated by the activation of P-glycoprotein (Gottesman and Pastan, 1993) .
P-glycoprotein has been found to be overexpressed in a variety of human cancers (Goldstein et al., 1989; Pinedo and Giaccone, 1995) . In particular, among solid tumors, detectable levels of expression of P-glycoprotein have been associated with a signi®cantly poor prognosis in neuroblastoma (Chan et al., 1991) , in childhood softtissue sarcomas (Chan et al., 1990) , and in osteosarcoma (Baldini et al., 1995; Chan et al., 1997) . These observations, in addition to the ®nding that overexpression of P-glycoprotein may occur without previous exposure to chemotherapy, has raised the possibility that this protein may be involved in a cascade of molecular events associated with tumor progression, and that it may constitute a biological marker of adverse prognosis (Pinedo and Giaccone, 1995; Bradley and Ling, 1994) . However, based on several experimental observations, since the mid 1970's it has been postulated that cells overexpressing Pglycoprotein are less aggressive than their non Pglycoprotein-expressing counterparts (Biedler et al. 1975) , indicating the existence of con¯ict statements derived from clinical and experimental data. Using osteosarcoma as a single model, we have recently shown that MDR does not appear to be associated with a more aggressive phenotype, either in vitro or in a clinical setting, and that the observed adverse prognostic value of P-glycoprotein in this tumor is not related to the higher metastatic potential of cells with P-glycoprotein overexpression, but rather to their ability to overcome the cytotoxic eects of anticancer drugs (Scotlandi et al., 1996) . These ®ndings have questioned the role of P-glycoprotein as an indicator of biological aggressiveness of osteosarcoma, suggesting the need for a better de®nition of this complex relationship (Baldini, 1997) . As a matter of fact, a reduction in the tumorigenic and metastatic ability of cancer cells appears to be a constant feature of MDR in many (Biedler and Spengler, 1994; Bernard et al., 1989; Bashir et al., 1994) , although not in all (Bradley et al., 1992) experimental models. Based on available data, however, the mechanisms triggering the loss of malignancy of MDR cells are still completely unknown, and, in particular, it is unclear whether P-glycoprotein may play a direct role in the reduced malignancy of MDR cells or if other mechanisms arise during the selection of MDR cells. On the basis of our previous observations on MDR osteosarcoma cells obtained by selection on doxorubicin, we decided to further investigate the association of P-glycoprotein expression with the reduced metastatic potential of MDR cells by analysing the in vitro and in vivo behavior of dierent MDR1 gene-transfected osteosarcoma cell clones.
Results

Characterization of MDR1 gene transfected clones
The RT ± PCR pro®le of MDR1 gene mRNA of representative transfectants is shown in Figure 1a . Bȳ ow cytometry, a positive immunostaining with the MRK16 monoclonal antibody was evident both in DOXO and MDR clones, respectively obtained by transfection with MDR1 gene followed by selection on DXR or by cotransfection with MDR1 and neo genes followed by selection on G418, but not in parental cell lines or in the control U-2/Neo clones, indicating that in all of the MDR transfectants the MDR1 gene product was properly processed and inserted into the plasma membrane (Figure 1b) . Compared to parental cell lines and U-2/Neo clones, all of the MDR1 transfected clones displayed higher degrees of resistance to DXR, that appeared to be related to the level of expression of P-glycoprotein at the cell surface (Table 1) . Notably, clones selected on G418 showed lower levels of resistance to DXR and of Pglycoprotein expression compared to clones selected on DXR, and their resistance levels were comparable to those observed in clinical settings. All of the MDR1 gene transfectants were cross-resistant to vincristine and actinomycin D, but not to methotrexate or cisplatin, showing a typical MDR phenotype (Table  2 ). Resistance to DXR could be reversed in the presence of verapamil (data not shown).
In vitro studies
No signi®cant dierences were observed in the doubling time of parental cells, control clones, or MDR1 transfectants, nor in their apoptotic rate of BrdUrd labeling index, indicating similar growth features. On the other hand, a signi®cantly lower cloning eciency in soft agar was found in all of the MDR1 transfectants with respect to controls, suggesting a less malignant behavior following the expression of P-glycoprotein (Table 3) . MDR osteosarcoma cells, selected on DXR, had been previously shown to present a number of phenotypic changes, including a higher level of osteoblastic dierentiation and an altered pattern of expression of some adhesion proteins and integrins (Scotlandi et al., 1996) . In the series of U-2 OS MDR1 transfectants, no dierence was observed in the expression of alkaline phosphatase, osteonectin, osteopontin, bone sialoprotein, or osteocalcin, all markers of the osteoblastic lineage, whereas in the two Saos-2 MDR1 transfectants a higher activity of alkaline phosphatase was recorded (data not shown). No signi®cant dierences were also found in the ICAM-1, LFA-3, or A-CAM pro®les (data not shown), whereas, in U-2/DOXO clones, the expression of a 2 b 1 and, at a lower level, of a 6 b 1 integrins was slightly increased, and the expression of both FGF-R and NGF-R was found to be reduced ( Figure 2 ). In Saos-2 transfectants, alterations in the expression of integrin or growth factor receptors appeared to be more likely due to clonal variations rather than to be related with P-glycoprotein expression ( Figure 3 ).
In vivo studies
After s.c. inoculation, none of the U-2 OS MDR1 transfectants was able to produce tumors. Similarly, 
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P-glycoprotein expression and malignancy in osteosarcoma K Scotlandi et al after i.v. injection, lung colonies were not observed for any of the U-2 OS MDR1 clones (Table 4) . In agreement with previously reported data (Rodan et al., 1987) , Saos-2 cells did not form tumors when s.c. injected into athymic mice (Table 5 ), but were able to give lung metastases in almost half of the animals. In MDR1 gene transfected clones of Saos-2 cells, however, a remarkable reduction of the metastatic ability was recorded, with a low or null capability to form lung colonies after i.v. injection. 
Discussion
The association of P-glycoprotein expression with aggressiveness and metastatic potential of tumor cells is an intriguing and poorly de®ned aspect of the MDR phenomenon. In fact, although a number of clinical observations on the prognostic signi®cance of Pglycoprotein expression in human malignancies have favoured the hypothesis that this protein may be considered as a distinctive marker of tumor progression that is related to a highly malignant phenotype (Bradley and Ling, 1994) , several studies using dierent experimental models have consistently shown a less aggressive behavior in cells with P-glycoprotein overexpression (Biedler et al., 1975; BeÂ nard et al., 1989; Bashir et al., 1994; Scotlandi et al., 1996) . Biedler ®rst identi®ed this peculiar phenomenon, and referred it as reverse transformation' to indicate that the in vitro acquisition of the MDR phenotype is associated with striking alterations in cell morphology and with the progressive loss of oncogenic potential of cancer cells (Biedler and Spengler, 1994) . The actual relevance of this phenomenon, however, has been subsequently challenged by the criticism that the reported normalization of MDR cells could be an incidental eect of the extreme conditions related to the very high levels of resistance that are commonly achieved in vitro, possibly without any connection with the phenotypic changes that are associated with MDR in clinical settings (Kerbel and MacDougall, 1993) . To determine whether or not P-glycoprotein is the critical factor in the phenomenon of reverse transformation, it would be necessary to analyse MDR cells with low levels of resistance, to evaluate the clinical course of homogeneous series of human cancers with dierent levels of P-glycoprotein expression, to compare the biological and clinical ®ndings in the same model, and to evaluate the in vitro and in vivo behavior of cell lines after transfection of the MDR1 gene. We have previously analysed the in vitro and in vivo behavior of several P-glycoprotein overexpressing osteosarcoma cells, obtained from U-2 OS and Saos-2 cell lines by stepwise increases in DXR concentration and showing dierent levels of MDR, ranging from 15 ± 330-fold increase compared to parental cells (Serra et al., 1993; Scotlandi et al., 1996) . In these series, the level of resistance appeared to be related to a lower tumorigenic and metastatic ability in athymic mice as well as to a reduced in vitro migratory and invasive ability and a more dierentiated phenotype. These ®ndings have been corroborated by clinical data. In fact, the time of appearance of metastases in a series of osteosarcoma patients treated with chemotherapy was signi®cantly shorter in the group of patients with no expression of P-glycoprotein in the primary lesion compared to the group with P-glycoprotein overexpression. Moreover, the incidence of P-glycoprotein overexpression was found to be higher among patients with localized disease than in patients with evidence of metastases at the time of diagnosis. Therefore, in osteosarcoma, the MDR phenotype does not appear to be associated with a more aggressive behavior, either in experimental or in clinical settings.
In order to further clarify the role of P-glycoprotein in reverse transformation and exclude the possible involvement of other mechanisms elicited by the continuous exposure to high doses of DXR, we analysed the in vitro and in vivo features of MDR clones obtained by transfection of osteosarcoma cells with a plasmid containing the MDR1 gene. In particular, we ®rst analysed two sets of U-2 OS MDR1 transfectants, selected in two dierent medium (containing DXR or G418, respectively) in order to avoid speculations due to the action of the drug rather than to the expression of P-glycoprotein. In fact, U-2/ MDR 117.1 and 117.2 have never been exposed to any chemotherapeutic drugs and, by analogy with transfectants previously obtained by others in LR73 ®broblasts, they may be considered as pure transfectants, since any altered phenotype for these cells has to be considered as due to Pglycoprotein overexpression alone. We did not observe signi®cance variations in the dierentiative features of any of U-2 OS MDR1 transfectants. On the other hand, the analysis of integrins showed an enhanced expression of a 2 b 1 and, at a lower level, of a 6 b 1 only in the U-2/DOXO transfectants, selected in DXR, but not in the U-2/MDR clones, selected in medium containing G418. The analysis of growth factor receptors showed a reduced expression of FGF-R and NGF-R in U-2/ DOXO, but not in U-2/MDR transfectants. These data may indicate that the expression of P-glycoprotein is not directly involved in these phenotypic alterations, and that the modulation of the expression of other cell surface molecules, including integrins and growth factor receptors, is rather due to the eects of DXR. Of the in vitro features, only the ability to grow in soft agar appeared to clearly distinguish the MDR1 transfectants from the parental cell line and the control U-2/Neo clones. The reduced anchorageindependent ability of MDR transfectants was found to be associated with progressively higher levels of expression of P-glycoprotein. The loss of malignant potential of MDR1 transfected clones was further con®rmed in vivo. In fact, none of the MDR1 transfectants was able to produce tumors or give pulmonary metastases, indicating that the acquisition of the MDR phenotype through the expression of Pglycoprotein at the cell surface is sucient to alter the tumorigenicity and the metastatic ability of tumor cells. All the ®ndings observed in U-2 OS transfectants were substantially con®rmed using a dierent osteosarcoma cell line. In fact, in Saos-2 cells, apart from a higher alkaline phosphatase activity, a marker of osteoblastic dierentiation, no dierences in the expression of integrins or growth factor receptors were observed in relation to P-glycoprotein expression. Moreover, although MDR1 gene expression was less clearly related with the inhibition of cell growth in soft agar in Saos-2 MDR1 transfectants compared to U-2 OS MDR1 transfectants, suppression of in vivo malignancy following the expression of MDR1 gene was further con®rmed by the study of the metastatic ability of Saos-2 cells. In fact, both MDR variants obtained by exposure to increasing DXR concentration (Serra et al., 1993) and MDR1 transfectants showed a signi®cant decrease in their ability to give lung colonies compared to parental cell line.
These ®ndings strongly supported the existence of a cause-and-eect relationship between the expression of P-glycoprotein and the reduced malignancy of MDR cells. So far, the phenomenon of reverse transform-ation has been uniformly observed in a sizable panel of cell lines overexpressing P-glycoprotein (Biedler et al., 1975; BeÂ nard et al., 1989; Biedler and Spengler, 1994; Bashir et al., 1994; Scotlandi et al., 1996) , but not in MDR cells showing no expression of P-glycoprotein (Mirski et al., 1987) . In this study, for the ®rst time, we demonstrated that the expression of the MDR1 gene is sucient to determine a normalization of MDR cells. In addition, we were also able to show that even low levels of MDR, comparable to those observed in clinical settings can in¯uence the ability of tumor cells to grow in soft-agar and in athymic mice. These ®ndings may have two relevant implications. From a clinical point of view, the demonstration that the prognostic value of P-glycoprotein is not linked to a more malignant phenotype opens new perspectives for the treatment of osteosarcomas with P-glycoprotein overexpression at the time of diagnosis, further supporting the potential value of resistance modi®ers in addition to conventional chemotherapy. From a biological point of view, the observation that the expression of P-glycoprotein is critical for the lower malignant potential of MDR cells raises new questions on its functions under physiological conditions. The observed reduction in the ability of MDR transfectants to grow in athymic mice that had been pre-treated with anti-asialo GM 1 antiserum to inhibit natural killer activity (Habu et al., 1981) , is likely due to an intrinsic feature of P-glycoprotein overexpressing cells rather than to an enhanced immunologic response. Although at the present time we cannot exclude that overexpression of MDR1 gene may result in the coexpression of other genes, that, in turn, might be responsible for a lower level of malignancy of MDR cells through the suppressed function of one or more genes involved in malignant transformation or the alteration in cell signaling, these data also suggest the existence of new functions for the P-glycoprotein. In this context, interesting speculations can be drawn from a number of recent reports suggesting a direct or indirect role of P-glycoprotein in the transport of dierent solutes, including ATP, Cl 7 , and cations . Although the hypothesis of the P-glycoprotein acting as an ion transporter regulator needs further documentation, it might help to explain the multiple functions of this protein as well as some unresolved complexities in the behavior of MDR cells.
Materials and methods
Cell culture and transfection U-2 OS and Saos-2 human osteosarcoma cells were maintained in Iscove's modi®ed Dulbecco's medium (IMDM) supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml) (GIBCO, Paisley, Scotland) and 10% heat inactivated fetal calf serum (FCS) (Biological Industries, Kibbutz Beth Haemek, Israel) at 378C in a humidi®ed 5% CO 2 atmosphere. The transfection of U-2 OS and Saos-2 cells was performed 24 h after seeding of 10 5 cells in 100-mm dishes using a standard calcium phosphate technique. Cells were transfected with 10 mg of pFR-CMV, an expression vector containing a full-length MDR1 cDNA kingly provided by P Borst (Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands) (Lincke et al., 1990) . After 24 h of exposure to DNA, cells were maintained in normal medium for 2 more days. Cultures were then exposed to selective medium containing 100 ng/ml of doxorubicin (DXR) (Sigma, St Louis, MO, USA) for Saos-2 cells and 300 ng/ml of DXR for U-2 OS cells, and re-fed every other day until selection of resistant colonies, after 2 weeks. Using glass cloning cylinders, several transfected clones were obtained. U-2/DOXO35 and U-2/DOXO23 clones as well as Saos-2/DOXO13 and Saos-2/DOXO26 are representative of this series. Using the same procedure, U-2 OS cells were also cotransfected with 10 mg of pFR-CMV and 1 mg of pSV2neo, an expression vector containing the neomycin resistance neo gene. These clones were selected in medium containing 500 mg/ml of the neomycin analogue G418 (Sigma). U-2/MDR117.1 and U-2/MDR117.2 clones are representative of this series. Controls were obtained by transfection with calf thymus DNA and pSV2neo, and selection with G418 (500 mg/ml). Clones U-2/Neo8 and U-2/Neo26 are representative of this series.
Analysis of growth and dierentiative features
After transfection, cells were maintained in selective medium for a maximum of eight in vitro passages before the in vitro and in vivo characterization. Cells were analysed in growth medium without DXR or G418. Doubling time of transfected clones was determined by daily harvesting of cells after seeding of 20 000 cell/cm 2 . Cell viability was determined by Trypan Blue dye exclusion. For the evaluation of BrdUrd labeling index, 5000 cells/cm 2 were seeded in IMDM plus 10% FCS. After 72 h, cell cultures were incubated with 10 mM BrdUrd (Sigma) for 1 h in a CO 2 atmosphere at 378C. Harvested cells were ®xed in 70% ethanol for 30 min. After DNA denaturation with 2N HCl for 30 min at room temperature, cells were washed with 0.1 M Na 2 B 4 O 7 , pH 8.5. 10 6 cells were then processed for indirect immuno¯uorescence staining, using a-BrdUrd (Euro-Diagnostics, Milan, Italy) diluted 1:4 as a primary antibody and analysed by¯ow cytometry. The analysis of apoptotic nuclei was assessed by morphological evaluation. In particular, 5000 cells/cm 2 were seeded in IMDM plus 10% FCS. After 72 h, cells were ®xed in methanol/acetic acid (3:1) for 15 min and stained with 50 ng/ml Hoechst 33258 (Sigma). Cells with three or more chromatin fragments were considered apoptotic. The percentage of apoptotic nuclei was evaluated out of 1000 ± 2000 nuclei. For the analysis of dierentiative features, cells were harvested 96 h after seeding, and smeared on glass slides. Cytospins were fixed with methanol-acetone (3:7) at 7208C for 10 min. The avidin-biotin-peroxidase complex method was used with the following polyclonal antibodies: anti-osteonectin LFbONII (1:200), anti-osteopontin LF-19 (1:100), antiosteocalcin LF-32 (1:200), and anti-bone sialoprotein-II LF-6 (1:100), all kindly provided by LW Fisher (Bone Research Branch, NIH, Bethesda, MD, USA). Alkaline phosphatase activity was measured in the conditioned medium of MDR1 transfectants and parental cell lines 4 days after cell seeding using p-nytrophenyl phosphate as a substrate, in accordance to the instructions of the manufacturer (Boehringer Mannheim).
P-glycoprotein expression
The expression of P-glycoprotein at the cell surface was analysed by indirect immuno¯uorescence and¯ow cytometry (FACScan, Becton Dickinson, San Jose, CA, USA) using the MRK-16 monoclonal antibody (Kamiya, Thousand Oaks, CA, USA) (1:100). The MDR1 gene mRNA was analysed by reverse transcriptase-polymerase chain reaction (RT-PCR). Total cellular RNA was isolated by TRIzol (Life Technologies, Gaithersburg, MD, USA), and 1 mg RNA was reverse-transcribed with the M-MLV (Life Technologies) in the presence of oligo-dT and dNTP. The RT ± PCR exponential phase was determined on 15 ± 40 cycles to allow a semiquantitative comparison among the cDNAs developed from identical reactions. Speci®c primers pairs for MDR1 cDNA (Murphy et al., 1990) were used to amplify a 286 bp fragment. b-actin primer pairs, obtained from Clontech (Palo Alto, CA, USA), were used to amplify a 479-bp fragment. Ampli®ed products were identi®ed by 2% agarose gel electrophoresis and ethidium bromide staining.
In vitro MDR
The degree of MDR was expressed as the ratio of drug concentration resulting in 50% inhibition of growth (IC 50 ) of MDR cells to that of parental cells. IC 50 values were determined by seeding 20 000 cells/cm 2 in IMDM with 10% FCS. After 24 h, medium was changed in IMDM with 10% FCS, without (control) or with dierent concentrations of DXR, vincristine (Sigma), actinomycin D (Sigma), methotrexate (Sigma), or cisplatin (Sigma). Working dilutions of all of the drugs were prepared immediately before use. After 96 h, cells were harvested with 0.25% trypsin-0.02% EDTA (Life Technologies) and counted to estimate the percentage of growth inhibition compared to the appropriate control. The reversal eect of verapamil (Sigma) on the in vitro sensitivity to DXR was analysed after 48 h of exposure to DXR or DXR plus verapamil (10 mM) using the same conditions as previously described.
Soft-agar assay
Anchorage-independent growth was determined in 0.33% agarose (FMC Bio Products, Rockland, ME, USA) with a 0.5% agarose underlay. Cell suspensions (10 000 ± 33 000 cells per 60-mm dish) were plated in a semi-solid medium (IMDM with 10% FCS containing 0.33% agarose). Colonies were counted after 14 days.
Adhesion molecules and integrin pattern
The expression of intercellular adhesion molecule-1 (ICAM-1), lymphocyte function-associated antigen-3 (LFA-3), and A-cell adhesion molecule (A-CAM), as well as of a 2 b 1 , a 4 b 1 , a 5 b 1 and a 6 b 1 integrins was determined bȳ ow cytometry after indirect immuno¯uorescence using the following monoclonal antibodies: LFA-3 (anti-LFA-3, Immunotech SA, Marseille, France), 1:20 dilution; CD54 ICAM (anti-ICAM-1, Immunotech SA), 1:10 dilution; GC-4 (anti-A-CAM, Sigma), 1:100 dilution; CDw49b VLA2 (anti-alpha 2 chain, a 2 b 1 , Immunotech SA), 1:10 dilution; CDw49d VLA4 (anti-alpha 4 chain, a 4 b 1 , Immumotech SA), 1:10 dilution; CDw49e VLA5 (anti-alpha 5 chain, a 5 b 1 , Immunotech SA), 1:10 dilution; CDw49f VLA6 (antialpha 6 chain, a 6 b 1 , Immunotech SA), 1:10 dilution.
Growth factor-receptor expression
The expression of speci®c membrane receptors was determined by¯ow cytometry after indirect immunofluorescence with the following primary antibodies: clone aIR3 (anti-human insulin-like growth factor I-receptor, IGF-IR, Oncogene Science, Cambridge, MA, USA), 1:10 dilution; clone 528 (anti-human epidermal growth factor-receptor, EGF-R, Oncogene Science), 1:40 dilution; clone 8211 (antihuman nerve growth factor-receptor, NGF-R, Boehringer Mannheim, Mannheim, Germany), 1:20 dilution; and antihuman ®broblast growth factor-receptor (FGF-R, Upstate Biotechnology, Lake Placid, NY, USA), 1:40 dilution.
Tumorigenic and metastatic ability in athymic mice
Female athymic 4 ± 5 week old Crl:nu/nu (CD-1) BR mice (Charles River Italia, Como, Italy) were used. Tumorigenicity was determined after s.c. injection of 30610 6 cells. Tumor growth was assessed twice weekly, and mice were sacri®ced 3 ± 4 months after inoculation. The metastatic ability was determined by injection of 2610 6 viable cells in a tail lateral vein. In order to obtain natural killer-depressed animals, mice were injected i.v. with 0.4 ml of a 1:25 dilution of anti-asialo GM 1 antiserum (Wako, DuÈ sseldorf, Germany) 24 h before cell inoculation. Two months later, mice were sacri®ced. The number of experimental pulmonary metastases was determined by counting with a stereomicroscope after staining with black India ink. Histologic sections obtained from the tumors grown in athymic mice were stained with hematoxylineosin.
Statistical analysis
Fisher's exact test was used to evaluate the association between two dichotomous values. Nonparametric Wilcoxon's rank sum test was used to compare the median values of lung colonies.
